Results 61 to 70 of about 19,474 (223)

Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells

Frontiers in Medicine, 2018
The efficacy of T cells expressing chimeric antigen receptors (CARs) for solid tumors has been limited by insufficient CAR T cell expansion and persistence.
Bilal Omer, Bilal Omer, Paul A. Castillo, Haruko Tashiro, Thomas Shum, Mai T. A. Huynh, Mara Cardenas, Miyuki Tanaka, Andrew Lewis, Tim Sauer, Robin Parihar, Robin Parihar, Natalia Lapteva, Michael Schmueck-Henneresse, Malini Mukherjee, Stephen Gottschalk, Stephen Gottschalk, Stephen Gottschalk, Cliona M. Rooney, Cliona M. Rooney, Cliona M. Rooney, Cliona M. Rooney   +21 more
doaj   +1 more source

Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors

Journal of Clinical Oncology
PURPOSE T cells modified with chimeric antigen receptors (CARTs) have demonstrated efficacy for hematologic malignancies; however, benefit for patients with CNS tumors has been limited.
Frank Y. Lin, Austin Stuckert, Candise Tat, Mark White, L. Ruggieri, Hui-Min Zhang, B. Mehta, N. Lapteva, Z. Mei, Angela M. Major, Sachin G. Thakkar, Thomas Shum, K. Parikh, Meng-Fen Wu, Holly B. Lindsay, Lauren D. Scherer, M. Shekar, P. Baxter, Tao Wang, B. Grilley, Karen K. Moeller, John Hicks, A. Roy, Jamie N. Anastas, F. Malbari, G. Aldave, M. Chintagumpala, S. Blaney, D. W. Parsons, M. K. Brenner, Helen E. Heslop, C. Rooney, Bilal Omer   +32 more
semanticscholar   +1 more source

Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells

International Journal of Molecular Sciences, 2023
Ganglioside GD2 is a well-established target expressed on multiple solid tumors, many of which are characterized by low treatment efficiency. Antibody-drug conjugates (ADCs) have demonstrated marked success in a number of solid tumors, and GD2-directed ...
D. Kalinovsky, I. Kholodenko, A. Kibardin, I. Doronin, E. Svirshchevskaya, D. Ryazantsev, M. Konovalova, F. Rozov, S. Larin, S. Deyev, R. Kholodenko   +10 more
semanticscholar   +1 more source

Two‐Dimensional Triferroics: From Fundamental Couplings to Multifunctional Applications

Advanced Science, EarlyView.
This graphic summarizes the three main types of currently reported 2D triferroic couplings. From the structural perspective, existing systems can be broadly classified into two categories, which exhibit distinct symmetry features and coupling behaviors. Beyond the lattice difference, a third type involves the interplay among ferroelectricity, magnetism,
Yang Li, Jialin Gong, Zhiqing Li
wiley   +1 more source

GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer

Frontiers in Oncology, 2023
BackgroundOvarian cancer (OC) is the deadliest gynecological cancer, often diagnosed at advanced stages. A fast and accurate diagnostic method for early-stage OC is needed.
Alba Galan, Arturo Papaluca, Arturo Papaluca, Ali Nejatie, Ali Nejatie, Emad Matanes, Emad Matanes, Fouad Brahimi, Wenyong Tong, Wenyong Tong, Ibrahim Yaseen Hachim, Amber Yasmeen, Euridice Carmona, Kathleen Oros Klein, Kathleen Oros Klein, Sonja Billes, Ahmed E. Dawod, Prasad Gawande, Anna Milik Jeter, Anne-Marie Mes-Masson, Anne-Marie Mes-Masson, Celia M. T. Greenwood, Celia M. T. Greenwood, Walter H. Gotlieb, Walter H. Gotlieb, H. Uri Saragovi, H. Uri Saragovi, H. Uri Saragovi   +27 more
doaj   +1 more source

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

Journal for ImmunoTherapy of Cancer, 2022
Background Aggressive primary brain tumors such as glioblastoma are uniquely challenging to treat. The intracranial location poses barriers to therapy, and the potential for severe toxicity.
T. Gargett, Lisa M. Ebert, N. Truong, P. Kollis, K. Sedivakova, W. Yu, E. Yeo, Nicole L. Wittwer, Briony L. Gliddon, Melinda N. Tea, R. Ormsby, Santosh I Poonnoose, J. Nowicki, O. Vittorio, D. Ziegler, S. Pitson, Michael P. Brown   +16 more
semanticscholar   +1 more source

Engineered Peptide Self‐Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors

Advanced Science, EarlyView.
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He, Xiao Lu, Chang qing Yang, Ran Zhang, Bo Wan, Xin Ni, Dong Mei   +6 more
wiley   +1 more source

Mechanism of GD2-induced platelet apoptosis.

, 2014
Both platelets pretreated with blocking anti-Siglec-7 PAb and untreated platelets were incubated with vehicle or GD2. A23187 was used as an apoptosis positive control. Different parameters of apoptosis pathways in platelets were analyzed.
Hind Hamzeh-Cognasse (78447), Isabelle Anselme-Bertrand (630772), Bruno Pozzetto (449862), Kim Anh Nguyen (416639), Fabrice Cognasse (78451), Olivier Garraud (78450), Patricia Chavarin (78448), Charles-Antoine Arthaud (630773), Sabine Palle (125131)   +8 more
core   +1 more source

In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. [PDF]

PLoS ONE, 2013
Ganglioside GD2 is a cell surface glycolipid that is highly expressed on cancer cells of neuroectodermal origin, including neuroblastoma, retinoblastoma, melanoma, sarcomas, brain tumors and small cell lung cancer.
Mahiuddin Ahmed, Yehuda Goldgur, Jian Hu, Hong-Fen Guo, Nai-Kong V Cheung   +4 more
doaj   +1 more source

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Journal for ImmunoTherapy of Cancer
Background Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies.
T. Gargett, N. Truong, B. Gardam, W. Yu, L. Ebert, Amy M. Johnson, E. Yeo, Nicole L. Wittwer, G. Tapia-Rico, Jesikah Logan, Purany Sivaloganathan, Maria Collis, Andrew Ruszkiewicz, Michael P. Brown   +13 more
semanticscholar   +1 more source